Goldman Sachs, BlackRock, and IFC Lead Star-Studded Anchor Book for Molbio Diagnostics IPO Alongside Six Premier Mutual Funds.

Molbio Diagnostics is set to make its debut in the Indian IPO market with a substantial issue size of INR 939.70 crore, consisting of a fresh issue of INR 200 crore and an offer for sale of INR 739.70 crore. The price band for the IPO is set between INR 768 and INR 807 per share, with a lot size of 18 shares, meaning a minimum investment of INR 14,526 at the upper band. The bidding window opens on August 10, 2026, and closes on August 12, 2026, with an anticipated listing date on August 17, 2026. A robust participation from domestic mutual funds, holding 67.51% of the anchor book, reflects significant institutional interest, which includes notable entries from global giants like Goldman Sachs and BlackRock.

The grey market sentiment surrounding the Molbio Diagnostics IPO indicates a promising outlook. As of August 8, 2026, the unofficial grey market premium (GMP) stood at INR 180, suggesting a potential listing price of INR 987, which translates to approximately a 22.3% gain over the upper price band of INR 807. Although the GMP reached as high as INR 220 prior to settling, it serves as an unofficial indicator of market sentiment, offering investors insights, albeit no guaranteed outcomes. The anchor book’s diverse participation and the healthy GMP point to favorable conditions for investor interest.

For Indian investors, the ongoing Molbio Diagnostics IPO represents both a significant opportunity and a potential risk. Brokerages have provided mixed recommendations, highlighting strengths in the company’s healthcare offerings and revenue model while cautioning against its reliance on government procurement and the concentration of revenue sources. The solid backing from reputable asset managers and mutual funds, alongside its unique position in the diagnostics market, paints a promising picture. However, investors should remain vigilant about the inherent risks associated with invested capital and the sustainability of growth in light of governmental dependency and product concentration.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)